- Home
- ATYR vs ABSI Comparison
ATYR vs ABSI Comparison
Compare ATYR & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- ABSI
- Stock Information
- Founded
- ATYR 2005
- ABSI 2011
- Country
- ATYR United States
- ABSI United States
- Employees
- ATYR N/A
- ABSI N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- ABSI Health Care
- Exchange
- ATYR Nasdaq
- ABSI Nasdaq
- Market Cap
- ATYR 327.0M
- ABSI 353.8M
- IPO Year
- ATYR 2015
- ABSI 2021
- Fundamental
- Price
- ATYR $2.79
- ABSI $2.24
- Analyst Decision
- ATYR Strong Buy
- ABSI Strong Buy
- Analyst Count
- ATYR 6
- ABSI 5
- Target Price
- ATYR $18.60
- ABSI $7.60
- AVG Volume (30 Days)
- ATYR 1.6M
- ABSI 3.6M
- Earning Date
- ATYR 03-13-2025
- ABSI 05-13-2025
- Dividend Yield
- ATYR N/A
- ABSI N/A
- EPS Growth
- ATYR N/A
- ABSI N/A
- EPS
- ATYR N/A
- ABSI N/A
- Revenue
- ATYR $235,000.00
- ABSI $4,534,000.00
- Revenue This Year
- ATYR $1,387.23
- ABSI $156.33
- Revenue Next Year
- ATYR $873.22
- ABSI $220.65
- P/E Ratio
- ATYR N/A
- ABSI N/A
- Revenue Growth
- ATYR N/A
- ABSI N/A
- 52 Week Low
- ATYR $1.42
- ABSI $2.23
- 52 Week High
- ATYR $4.66
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- ATYR 33.98
- ABSI 28.34
- Support Level
- ATYR $3.20
- ABSI $2.81
- Resistance Level
- ATYR $3.94
- ABSI $2.62
- Average True Range (ATR)
- ATYR 0.22
- ABSI 0.18
- MACD
- ATYR -0.09
- ABSI -0.04
- Stochastic Oscillator
- ATYR 4.97
- ABSI 0.46
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.